MCID: CNT033
MIFTS: 47

Central Nervous System Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Central Nervous System Cancer

MalaCards integrated aliases for Central Nervous System Cancer:

Name: Central Nervous System Cancer 12 54 15 17
Malignant Neoplasm of Central Nervous System 12
Neoplasm of the Central Nervous System 6
Neoplasm of Central Nervous System 12
Central Nervous System Neoplasms 43
Central Nervous System Neoplasm 17
Central Nervous System Tumors 12
Central Nervous System Tumor 12
Malignant Tumor of Cns 12
Cns Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3620
MeSH 43 D016543
NCIt 49 C4627 C9293
SNOMED-CT 67 126951006 372062007
ICD10 32 C72.9
UMLS 71 C0085136 C0348374

Summaries for Central Nervous System Cancer

Disease Ontology : 12 A nervous system cancer that is located in the central nervous system.

MalaCards based summary : Central Nervous System Cancer, also known as malignant neoplasm of central nervous system, is related to central nervous system benign neoplasm and central nervous system hematologic cancer. An important gene associated with Central Nervous System Cancer is SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1), and among its related pathways/superpathways are MicroRNAs in cancer and Alzheimers Disease. The drugs Magnesium Sulfate and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include central nervous system, brain and t cells.

Related Diseases for Central Nervous System Cancer

Diseases related to Central Nervous System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 474, show less)
# Related Disease Score Top Affiliating Genes
1 central nervous system benign neoplasm 33.5 SERPINA3 MIR34A MIR125B1 KDM4C H2AC18
2 central nervous system hematologic cancer 33.4 MIR199A1 MIR124-1 KDM4C
3 brain cancer 33.2 SMARCB1 SERPINA3 MIR9-1 MIR548B MIR21 MIR19A
4 meningioma, familial 32.2 SMARCB1 SERPINA3 MIR548B MIR34A MIR15B H2AC18
5 grade iii astrocytoma 31.8 SERPINA3 MIR196A1 MIR10A KDM4C H2AC18
6 rhabdoid cancer 31.8 SMARCB1 KDM4C H2AC18
7 secretory meningioma 31.6 SMARCB1 SERPINA3
8 fibrillary astrocytoma 31.4 SERPINA3 KDM4C H2AC18
9 leukemia, acute myeloid 31.3 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
10 leukemia, chronic myeloid 31.1 MIR9-1 MIR19A MIR199A1 MIR196A1 MIR17 MIR125A
11 demyelinating disease 31.0 SERPINA3 MIR9-1 MIR15B MIR155 MIR125A MIR124-1
12 in situ carcinoma 30.9 SERPINA3 MIR548B MIR17 H2AC18
13 glioma 30.9 MIR34A MIR21 MIR19A MIR17 MIR15B
14 leukemia, acute lymphoblastic 30.9 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17 MIR155
15 medulloblastoma 30.9 SMARCB1 MIR9-1 MIR34A MIR19A MIR17 MIR125A
16 esophageal cancer 30.8 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR155
17 brain glioma 30.8 MIR34A MIR10A KDM4C
18 lymphoma, non-hodgkin, familial 30.8 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
19 renal cell carcinoma, nonpapillary 30.8 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR17
20 placenta disease 30.8 SERPINA3 MIR199A1 H2AC18
21 leukemia, chronic lymphocytic 30.7 MIR9-1 MIR34A MIR21 MIR19A MIR199A1 MIR196A1
22 pancreatic cancer 30.7 SERPINA3 MIR34A MIR21 MIR199A1 MIR196A1 MIR17
23 kidney cancer 30.6 MIR21 MIR199A1 MIR17 H2AC18
24 lung cancer 30.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR19A MIR199A1
25 mismatch repair cancer syndrome 11.7
26 meningioma, radiation-induced 11.6
27 cellular ependymoma 11.6
28 neurilemmomatosis 11.6
29 subependymal giant cell astrocytoma 11.6
30 glioma susceptibility 2 11.3
31 glioma susceptibility 9 11.3
32 schwannomatosis 1 11.2
33 central nervous system primitive neuroectodermal neoplasm 11.2
34 diffuse midline glioma, h3 k27m-mutant 11.2
35 central nervous system sarcoma 11.2
36 cranial nerve neoplasm 11.2
37 central nervous system germ cell tumor 11.2
38 central nervous system melanocytic neoplasm 11.2
39 central nervous system mesenchymal non-meningothelial tumor 11.2
40 spinal cancer 11.2
41 chromosomal deletion syndrome 10.8 MIR9-1 MIR196A1 MIR17 MIR15B H2AC18
42 germ cell and embryonal cancer 10.8 SERPINA3 MIR9-1 KDM4C H2AC18
43 miyoshi muscular dystrophy 1 10.8 MIR34A MIR21 MIR155
44 muscle cancer 10.8 SMARCB1 SERPINA3 MIR9-1 MIR199A1 MIR196A1 H2AC18
45 esophagus adenocarcinoma 10.8 MIR21 MIR199A1 MIR196A1 MIR145
46 oropharynx cancer 10.8 SERPINA3 MIR9-1 MIR199A1 H2AC18
47 skeletal muscle cancer 10.8 SMARCB1 SERPINA3 MIR199A1 H2AC18
48 endocrine organ benign neoplasm 10.8 SERPINA3 MIR21 MIR199A1 KDM4C H2AC18
49 fetal alcohol spectrum disorder 10.8 MIR9-1 KDM4C H2AC18
50 cardiovascular organ benign neoplasm 10.8 SERPINA3 MIR10A KDM4C H2AC18
51 intrinsic cardiomyopathy 10.8 MIR21 MIR199A1 MIR124-1 MIR10A H2AC18
52 fetal alcohol syndrome 10.8 MIR9-1 KDM4C H2AC18
53 extrinsic cardiomyopathy 10.8 SERPINA3 MIR21 MIR199A1 MIR10A H2AC18
54 heart valve disease 10.8 SERPINA3 MIR21 MIR199A1 MIR17 H2AC18
55 bronchial disease 10.8 SERPINA3 MIR21 MIR17 MIR155 H2AC18
56 chromosome 16p13.3 deletion syndrome, proximal 10.8 MIR9-1 KDM4C H2AC18
57 testicular disease 10.8 SERPINA3 MIR199A1 KDM4C H2AC18
58 germ cell cancer 10.8 SERPINA3 MIR9-1 MIR199A1 KDM4C H2AC18
59 uveal disease 10.8 SERPINA3 MIR9-1 MIR199A1 MIR125A H2AC18
60 aortic valve disease 2 10.8 SERPINA3 MIR34A MIR21 MIR199A1 MIR17
61 inclusion body myositis 10.8 SERPINA3 MIR34A MIR21 MIR155
62 heart conduction disease 10.8 SERPINA3 MIR21 MIR199A1 H2AC18
63 primary mediastinal b-cell lymphoma 10.8 MIR9-1 MIR155 KDM4C
64 tongue disease 10.8 MIR21 MIR199A1 MIR196A1 MIR17 MIR15B MIR145
65 lipid storage disease 10.8 SERPINA3 MIR21 MIR199A1 MIR155 H2AC18 ARSA
66 ovarian serous carcinoma 10.8 MIR21 MIR199A1 MIR145 MIR125A
67 nut midline carcinoma 10.8 SMARCB1 KDM4C H2AC18
68 bile duct cancer 10.8 MIR9-1 MIR21 MIR199A1 MIR17 MIR145 KDM4C
69 retinal cancer 10.8 MIR9-1 MIR199A1 MIR196A1 MIR17 MIR125A KDM4C
70 autosomal recessive disease 10.8 SERPINA3 MIR9-1 KDM4C H2AC18 ARSA
71 thyroid gland disease 10.8 SERPINA3 MIR9-1 MIR199A1 MIR17 MIR125A H2AC18
72 infratentorial cancer 10.8 SMARCB1 MIR9-1 MIR19A MIR199A1 MIR196A1 MIR17
73 ocular cancer 10.8 MIR9-1 MIR199A1 MIR196A1 MIR17 MIR125A KDM4C
74 pre-malignant neoplasm 10.8 SERPINA3 MIR548B MIR17 H2AC18
75 cervix carcinoma 10.8 SERPINA3 MIR199A1 MIR15B MIR155 H2AC18
76 muscular disease 10.8 SERPINA3 MIR9-1 MIR199A1 MIR196A1 MIR10A H2AC18
77 x-linked monogenic disease 10.8 SERPINA3 MIR9-1 MIR196A1 H2AC18
78 eye degenerative disease 10.8 SERPINA3 MIR17 KDM4C H2AC18
79 ampulla of vater adenocarcinoma 10.8 MIR196A1 MIR17 MIR145
80 luminal breast carcinoma a 10.8 MIR21 KDM4C H2AC18
81 primary bacterial infectious disease 10.8 SERPINA3 MIR21 MIR155 MIR125A H2AC18
82 specific developmental disorder 10.8 SERPINA3 MIR9-1 KDM4C H2AC18
83 lysosomal storage disease 10.8 SERPINA3 MIR21 MIR199A1 MIR155 H2AC18 ARSA
84 bone resorption disease 10.8 SERPINA3 MIR199A1 MIR196A1 H2AC18
85 autoimmune disease of musculoskeletal system 10.8 SERPINA3 MIR21 MIR196A1 MIR155 MIR125A H2AC18
86 aortic disease 10.8 SERPINA3 MIR21 MIR199A1 MIR17 MIR145
87 larynx cancer 10.8 MIR34A MIR21 MIR196A1 MIR17 MIR155 MIR125A
88 muscle tissue disease 10.8 SERPINA3 MIR9-1 MIR199A1 H2AC18
89 rectum cancer 10.8 MIR21 MIR17 MIR145 MIR125A
90 gallbladder disease 10.8 SERPINA3 MIR199A1 MIR196A1 MIR17 MIR145
91 colonic benign neoplasm 10.8 SERPINA3 KDM4C H2AC18
92 tonsil cancer 10.8 SERPINA3 MIR199A1 H2AC18
93 laryngeal disease 10.8 MIR9-1 MIR34A MIR21 MIR196A1 MIR17 MIR155
94 suppression of tumorigenicity 12 10.8 SERPINA3 MIR199A1 MIR145 KDM4C H2AC18
95 mature b-cell neoplasm 10.8 MIR9-1 MIR199A1 MIR196A1 MIR17 MIR155 MIR125A
96 autoimmune disease of central nervous system 10.8 SERPINA3 MIR9-1 MIR15B MIR155 MIR125A MIR124-1
97 cerebral arterial disease 10.8 SERPINA3 MIR199A1 MIR145 MIR125B1 MIR125A
98 coronavirus infectious disease 10.8 SERPINA3 MIR17 H2AC18
99 bone sarcoma 10.8 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR17 MIR125A
100 digeorge syndrome 10.8 MIR9-1 MIR196A1 MIR17 MIR15B H2AC18
101 nasopharyngeal disease 10.8 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17 MIR15B
102 non-syndromic intellectual disability 10.8 SMARCB1 MIR9-1 H2AC18
103 biliary tract disease 10.8 SERPINA3 MIR9-1 MIR199A1 MIR196A1 MIR17 MIR145
104 bile duct disease 10.8 SERPINA3 MIR9-1 MIR199A1 MIR196A1 MIR17 MIR145
105 pulmonary disease, chronic obstructive 10.8 SERPINA3 MIR21 MIR199A1 MIR17 H2AC18
106 intestinal benign neoplasm 10.8 SERPINA3 MIR21 MIR199A1 MIR196A1 MIR17 MIR145
107 chromosomal disease 10.8 SERPINA3 MIR9-1 MIR21 MIR196A1 MIR17 MIR15B
108 inherited metabolic disorder 10.8 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
109 melanoma in congenital melanocytic nevus 10.8 MIR199A1 KDM4C H2AC18
110 facioscapulohumeral muscular dystrophy 1 10.8 MIR34A MIR21 MIR155 KDM4C
111 diffuse large b-cell lymphoma 10.8 MIR21 MIR199A1 MIR17 MIR155 MIR145 MIR10A
112 gastrointestinal system benign neoplasm 10.8 SERPINA3 MIR21 MIR199A1 MIR196A1 MIR17 MIR124-1
113 pancreatic ductal adenocarcinoma 10.8 MIR21 MIR199A1 MIR196A1 MIR155 MIR145
114 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.8 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17
115 oral cavity cancer 10.8 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17 MIR145
116 bone marrow cancer 10.8 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR17
117 pleural disease 10.7 SERPINA3 MIR199A1 MIR17 MIR125B1 MIR125A MIR124-1
118 autonomic nervous system neoplasm 10.7 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
119 peripheral nervous system neoplasm 10.7 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
120 disease of mental health 10.7 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR17 MIR15B
121 autosomal genetic disease 10.7 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17
122 ovarian disease 10.7 MIR9-1 MIR21 MIR199A1 MIR17 MIR145 MIR125B1
123 bile duct adenocarcinoma 10.7 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17
124 esophageal disease 10.7 MIR34A MIR21 MIR199A1 MIR196A1 MIR17 MIR145
125 overnutrition 10.7 SERPINA3 MIR34A MIR21 MIR199A1 MIR196A1 MIR17
126 parasitic helminthiasis infectious disease 10.7 SERPINA3 MIR21 H2AC18
127 glucose metabolism disease 10.7 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17
128 pharynx cancer 10.7 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17
129 cell type benign neoplasm 10.7 SERPINA3 MIR21 MIR199A1 MIR196A1 MIR17 MIR15B
130 hypersensitivity reaction type iv disease 10.7 SERPINA3 MIR155 H2AC18
131 eye disease 10.7 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17
132 upper respiratory tract disease 10.7 SERPINA3 MIR9-1 MIR21 MIR19A MIR199A1 MIR196A1
133 leukocyte disease 10.7 SERPINA3 MIR21 MIR199A1 MIR196A1 MIR17 MIR155
134 mouth disease 10.7 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17
135 dermatomyositis 10.7 MIR34A MIR21 MIR155
136 oral squamous cell carcinoma 10.7 MIR9-1 MIR34A MIR21 MIR19A MIR199A1 MIR17
137 bladder disease 10.7 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR17
138 sphingolipidosis 10.7 SERPINA3 H2AC18 ARSA
139 proliferative fasciitis 10.7 SMARCB1 SERPINA3
140 mycobacterium tuberculosis 1 10.7 SERPINA3 MIR21 MIR155 H2AC18
141 skin disease 10.7 SERPINA3 MIR21 MIR199A1 MIR196A1 MIR17 MIR155
142 lymphangioma 10.7 SERPINA3 KDM4C H2AC18
143 squamous cell carcinoma, head and neck 10.7 MIR9-1 MIR21 MIR19A MIR199A1 MIR196A1 MIR17
144 bone inflammation disease 10.7 SERPINA3 MIR34A MIR21 MIR199A1 MIR196A1 MIR17
145 peripheral nerve schwannoma 10.7 SMARCB1 SERPINA3
146 amino acid metabolic disorder 10.7 SERPINA3 KDM4C H2AC18
147 ovary epithelial cancer 10.7 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17
148 malignant ovarian surface epithelial-stromal neoplasm 10.7 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17
149 heart septal defect 10.7 MIR199A1 MIR17 H2AC18
150 integumentary system disease 10.7 SERPINA3 MIR9-1 MIR21 MIR19A MIR199A1 MIR196A1
151 non-alcoholic fatty liver disease 10.7 MIR34A MIR21 MIR199A1 MIR17 MIR155
152 melanoma, uveal 10.7 MIR9-1 MIR199A1 MIR125A H2AC18
153 acquired metabolic disease 10.7 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17
154 cervical cancer 10.7 MIR9-1 MIR34A MIR21 MIR19A MIR196A1 MIR17
155 lung cancer susceptibility 3 10.7 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17
156 clear cell renal cell carcinoma 10.7 MIR21 MIR199A1 MIR155 MIR145 MIR10A
157 cardiovascular system disease 10.7 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR17
158 bladder cancer 10.7 MIR9-1 MIR34A MIR21 MIR199A1 MIR17 MIR145
159 benign ependymoma 10.7
160 diabetes mellitus, noninsulin-dependent 10.7 SERPINA3 MIR21 MIR199A1 MIR196A1 MIR17 MIR125A
161 toxic encephalopathy 10.7 SERPINA3 MIR9-1 H2AC18
162 myeloma, multiple 10.7 SERPINA3 MIR9-1 MIR21 MIR19A MIR199A1 MIR196A1
163 cervix disease 10.7 MIR9-1 MIR34A MIR21 MIR19A MIR199A1 MIR196A1
164 bacterial pneumonia 10.7 SERPINA3 MIR155 H2AC18
165 spinal meningioma 10.7
166 lymphoplasmacyte-rich meningioma 10.7
167 endocrine system disease 10.7 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR196A1 MIR17
168 pancreatitis, hereditary 10.7 MIR199A1 MIR125B1 MIR125A
169 body mass index quantitative trait locus 11 10.7 SERPINA3 MIR34A MIR21 MIR199A1 MIR196A1 MIR17
170 ovary adenocarcinoma 10.7 SERPINA3 MIR17 H2AC18
171 retinal vascular disease 10.7 MIR21 MIR199A1 H2AC18
172 male reproductive system disease 10.7 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
173 prostate disease 10.7 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
174 male reproductive organ cancer 10.7 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
175 lymphatic system disease 10.7 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
176 colonic disease 10.7 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
177 urinary system disease 10.7 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
178 lymphatic system cancer 10.7 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
179 heart disease 10.7 MIR21 MIR199A1 MIR17 MIR155 MIR145 MIR124-1
180 breast disease 10.7 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
181 pancreas disease 10.7 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
182 bone remodeling disease 10.7 SERPINA3 MIR199A1 H2AC18
183 large intestine cancer 10.7 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
184 cervix small cell carcinoma 10.7 MIR199A1 MIR145
185 pervasive developmental disorder 10.7 SERPINA3 MIR9-1 KDM4C H2AC18
186 thoracic cancer 10.7 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
187 uterine anomalies 10.7 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
188 gastric cancer 10.6 SMARCB1 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1
189 intestinal disease 10.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR19A MIR199A1
190 prion disease 10.6 SERPINA3 MIR9-1 H2AC18
191 female reproductive system disease 10.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
192 hypertension, essential 10.6 SERPINA3 MIR21 MIR17 MIR155 MIR145 MIR125B1
193 endocrine gland cancer 10.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
194 bone cancer 10.6 SERPINA3 MIR9-1 MIR548B MIR21 MIR199A1 MIR196A1
195 polymyositis 10.6 MIR21 MIR155
196 spinal disease 10.6 SERPINA3 MIR9-1 MIR548B MIR21 MIR199A1 MIR196A1
197 reproductive system disease 10.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
198 leiomyoma, uterine 10.6 MIR34A MIR21 MIR10A
199 immune system disease 10.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
200 wilms tumor 1 10.6 SMARCB1 SERPINA3 MIR125A H2AC18
201 connective tissue disease 10.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
202 arteries, anomalies of 10.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
203 ovarian cancer 10.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
204 central nervous system disease 10.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
205 gastrointestinal system disease 10.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR19A MIR199A1
206 prostate cancer 10.6 SERPINA3 MIR34A MIR21 MIR199A1 MIR17 MIR145
207 gastrointestinal system cancer 10.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR19A MIR199A1
208 substance abuse 10.6 SERPINA3 MIR199A1 H2AC18
209 respiratory system cancer 10.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR19A MIR199A1
210 sezary's disease 10.6 MIR34A MIR199A1 MIR17
211 connective tissue cancer 10.6 SERPINA3 MIR9-1 MIR548B MIR34A MIR21 MIR199A1
212 hepatocellular carcinoma 10.6 SMARCB1 SERPINA3 MIR9-1 MIR34A MIR21 MIR19A
213 nervous system disease 10.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR19A MIR199A1
214 hematologic cancer 10.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR19A MIR199A1
215 respiratory system disease 10.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR19A MIR199A1
216 meningothelial meningioma 10.6 SERPINA3 MIR34A
217 colorectal cancer 10.6 SERPINA3 MIR9-1 MIR34A MIR21 MIR19A MIR199A1
218 alcohol use disorder 10.6 MIR199A1 KDM4C H2AC18
219 clear cell chondrosarcoma 10.5 SERPINA3 H2AC18
220 ovarian serous cystadenocarcinoma 10.5 SERPINA3 MIR196A1 MIR17
221 laryngeal squamous cell carcinoma 10.5 MIR34A MIR21 MIR155
222 renal fibrosis 10.4 MIR21 MIR199A1 MIR196A1
223 rhabdoid tumor predisposition syndrome 1 10.4
224 neurofibromatosis 10.4
225 atypical teratoid rhabdoid tumor 10.4
226 craniopharyngioma 10.4
227 juvenile pilocytic astrocytoma 10.4
228 malignant glioma 10.3
229 ganglioglioma 10.3
230 adenoma 10.3
231 pineoblastoma 10.3
232 pituitary adenoma 10.3
233 neutropenia 10.3
234 hemangiopericytoma, malignant 10.2
235 mucositis 10.2
236 tuberous sclerosis 10.2
237 supratentorial primitive neuroectodermal tumor 10.2
238 pleomorphic xanthoastrocytoma 10.2
239 low-grade astrocytoma 10.2
240 myxopapillary ependymoma 10.2
241 coronary heart disease 1 10.2 MIR17 MIR155 MIR145
242 neurilemmoma 10.2
243 malignant ependymoma 10.2
244 brain tumor, childhood 10.2
245 pituitary tumors 10.2
246 glioma susceptibility 1 10.1
247 retinoblastoma 10.1
248 central neurocytoma 10.1
249 thrombocytopenia 10.1
250 germinoma 10.1
251 familial retinoblastoma 10.1
252 mixed glioma 10.1
253 hemangioblastoma 10.1
254 anaplastic ependymoma 10.1
255 germ cells tumors 10.1
256 high-grade astrocytoma 10.1
257 von hippel-lindau syndrome 10.1
258 papilloma of choroid plexus 10.1
259 acoustic neuroma 10.1
260 squamous cell papilloma 10.1
261 papilloma 10.1
262 rhabdomyosarcoma 10.1
263 choroid plexus cancer 10.1
264 brain stem glioma 10.1
265 brain edema 10.1
266 pilomyxoid astrocytoma 10.1
267 astroblastoma 10.1
268 neuroblastoma 10.1
269 intracranial hypertension 10.1
270 pineocytoma 10.1
271 monosomy 22 10.1
272 thyroid carcinoma 10.1
273 glioblastoma multiforme 10.0
274 astrocytoma 10.0
275 breast cancer 10.0
276 kaposi sarcoma 10.0
277 li-fraumeni syndrome 10.0
278 tuberous sclerosis 1 10.0
279 chordoma 10.0
280 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.0
281 neuroblastoma 1 10.0
282 insulin-like growth factor i 10.0
283 ataxia and polyneuropathy, adult-onset 10.0
284 yemenite deaf-blind hypopigmentation syndrome 10.0
285 li-fraumeni syndrome 2 10.0
286 tumor predisposition syndrome 10.0
287 brain meningioma 10.0
288 hydrocephalus 10.0
289 papilledema 10.0
290 neuroma 10.0
291 brain germinoma 10.0
292 dysembryoplastic neuroepithelial tumor 10.0
293 gliosarcoma 10.0
294 central nervous system lymphoma 10.0
295 central nervous system germinoma 10.0
296 ependymoblastoma 10.0
297 pineal gland cancer 10.0
298 rhabdoid meningioma 10.0
299 clear cell ependymoma 10.0
300 malignant peripheral nerve sheath tumor 10.0
301 paraplegia 10.0
302 childhood leukemia 10.0
303 neurofibroma 10.0
304 anaplastic pleomorphic xanthoastrocytoma 10.0
305 optic pathway glioma 10.0
306 papillary glioneuronal tumors 10.0
307 primary central nervous system lymphoma 10.0
308 seizure disorder 10.0
309 spasticity 10.0
310 traumatic brain injury 10.0
311 angiocentric glioma 10.0
312 papillary tumor of the pineal region 10.0
313 rare tumor 10.0
314 lipomatosis, multiple 9.9
315 langerhans cell histiocytosis 9.9
316 pleomorphic lipoma 9.9
317 granular cell tumor 9.9
318 lipomatosis 9.9
319 teratoma 9.9
320 histiocytosis 9.9
321 ganglioneuroblastoma 9.9
322 erdheim-chester disease 9.9
323 juvenile xanthogranuloma 9.9
324 gliomatosis cerebri 9.9
325 melanomatosis 9.9
326 pathologic nystagmus 9.9
327 primary melanoma of the central nervous system 9.9
328 paresthesia 9.9
329 diffuse leptomeningeal melanocytosis 9.9
330 fragile x syndrome 9.9
331 aging 9.9
332 ptosis 9.9
333 sarcoma 9.9
334 central nervous system leukemia 9.9
335 hemangioma 9.9
336 capillary hemangioma 9.9
337 insulinoma 9.9
338 spindle cell sarcoma 9.9
339 intracranial primitive neuroectodermal tumor 9.9
340 bronchitis 9.9
341 cerebellar liponeurocytoma 9.9
342 amyloidosis 9.9
343 hypopituitarism 9.9
344 stomatitis 9.9
345 47,xyy 9.9
346 lymphoma, hodgkin, classic 9.8
347 sleep apnea 9.8
348 lymphoma 9.8
349 brucellosis 9.8
350 oligodendroglioma 9.8
351 mutism 9.8
352 acute disseminated encephalomyelitis 9.8
353 anaplastic oligodendroglioma 9.8
354 cerebellar degeneration 9.8
355 paraneoplastic cerebellar degeneration 9.8
356 encephalopathy 9.8
357 glial tumor 9.8
358 leukemia, chronic lymphocytic 2 9.8
359 multiple sclerosis 9.8
360 multiple endocrine neoplasia, type i 9.8
361 hand skill, relative 9.8
362 enchondromatosis, multiple, ollier type 9.8
363 pulmonary hypertension, primary, 1 9.8
364 sarcoidosis 1 9.8
365 small cell cancer of the lung 9.8
366 thyroid cancer, nonmedullary, 1 9.8
367 ataxia-telangiectasia 9.8
368 chondrosarcoma 9.8
369 mowat-wilson syndrome 9.8
370 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.8
371 hydrocephalus, congenital, 1 9.8
372 immune deficiency disease 9.8
373 proteasome-associated autoinflammatory syndrome 1 9.8
374 reticulum cell sarcoma 9.8
375 thrombocytopenia 3 9.8
376 pituitary adenoma, prolactin-secreting 9.8
377 wilms tumor 5 9.8
378 sickle cell anemia 9.8
379 bone mineral density quantitative trait locus 3 9.8
380 juvenile myelomonocytic leukemia 9.8
381 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.8
382 ewing sarcoma 9.8
383 glioma susceptibility 3 9.8
384 myelodysplastic syndrome 9.8
385 graft-versus-host disease 9.8
386 multiple enchondromatosis, maffucci type 9.8
387 alacrima, achalasia, and mental retardation syndrome 9.8
388 hyperprolactinemia 9.8
389 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.8
390 familial adenomatous polyposis 9.8
391 exanthem 9.8
392 small cell carcinoma 9.8
393 paraganglioma 9.8
394 hemorrhagic cystitis 9.8
395 connective tissue benign neoplasm 9.8
396 inguinal hernia 9.8
397 childhood acute lymphocytic leukemia 9.8
398 hepatic veno-occlusive disease 9.8
399 sensorineural hearing loss 9.8
400 siderosis 9.8
401 abducens nerve disease 9.8
402 arteriovenous malformation 9.8
403 sciatic neuropathy 9.8
404 pica disease 9.8
405 chagas disease 9.8
406 neurogenic bladder 9.8
407 acute leukemia 9.8
408 telangiectasis 9.8
409 neurosarcoidosis 9.8
410 facial paralysis 9.8
411 hypothyroidism 9.8
412 cystitis 9.8
413 epilepsy 9.8
414 malignant fibrous histiocytoma 9.8
415 constipation 9.8
416 severe acute respiratory syndrome 9.8
417 adenocarcinoma 9.8
418 giant cell glioblastoma 9.8
419 multiple endocrine neoplasia 9.8
420 spinal cord disease 9.8
421 myelitis 9.8
422 fibrosarcoma 9.8
423 plague 9.8
424 choriocarcinoma 9.8
425 chordoid glioma 9.8
426 cranial nerve palsy 9.8
427 large cell medulloblastoma 9.8
428 childhood medulloblastoma 9.8
429 cerebral neuroblastoma 9.8
430 fibrous histiocytoma 9.8
431 hypokalemia 9.8
432 medulloepithelioma 9.8
433 ganglioneuroma 9.8
434 poliomyelitis 9.8
435 sleep disorder 9.8
436 ovarian small cell carcinoma 9.8
437 acquired immunodeficiency syndrome 9.8
438 progressive multifocal leukoencephalopathy 9.8
439 cowden syndrome 9.8
440 b-cell lymphoma 9.8
441 small-cell carcinoma of the ovary of hypercalcemic type 9.8
442 ileus 9.8
443 myeloid leukemia 9.8
444 neuropathy 9.8
445 learning disability 9.8
446 narcolepsy 9.8
447 central sleep apnea 9.8
448 diabetes insipidus 9.8
449 meningitis 9.8
450 alopecia 9.8
451 48,xyyy 9.8
452 chromosomal triplication 9.8
453 chronic graft versus host disease 9.8
454 desmoplastic infantile ganglioglioma 9.8
455 primary angiitis of the central nervous system 9.8
456 rosette-forming glioneuronal tumor 9.8
457 subependymoma 9.8
458 transverse myelitis 9.8
459 back pain 9.8
460 brain and spinal tumors 9.8
461 cytomegalovirus infection 9.8
462 foot drop 9.8
463 headache 9.8
464 hypersomnia 9.8
465 spinal cord injury 9.8
466 superficial siderosis 9.8
467 extraventricular neurocytoma 9.8
468 central nervous system embryonal tumor 9.8
469 argyria 9.8
470 rela fusion-positive ependymoma 9.8
471 cerebral amyloid angiopathy, cst3-related 9.7
472 third ventricle chordoid glioma 9.7
473 delusional disorder 9.7
474 syringohydromyelia 9.7

Graphical network of the top 20 diseases related to Central Nervous System Cancer:



Diseases related to Central Nervous System Cancer

Symptoms & Phenotypes for Central Nervous System Cancer

Drugs & Therapeutics for Central Nervous System Cancer

Drugs for Central Nervous System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 412, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
2
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
4
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
5
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
6
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
7 Orange Approved Phase 3
8
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
9
Cisatracurium Approved Phase 3 96946-41-7
10
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
11
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
12
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
13
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
14
Trioxsalen Approved Phase 3 3902-71-4 5585
15
Ondansetron Approved Phase 3 99614-02-5 4595
16
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
17
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
18
Ofloxacin Approved Phase 3 82419-36-1 4583
19
Thioguanine Approved Phase 3 154-42-7 2723601
20
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
21
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
22 Mitolactol Investigational Phase 3 10318-26-0
23 Molgramostim Investigational Phase 3 99283-10-0
24 Anesthetics Phase 3
25 glucocorticoids Phase 3
26 Antihypertensive Agents Phase 3
27 Vasoconstrictor Agents Phase 3
28 Amoxicillin-Potassium Clavulanate Combination Phase 3
29 beta-Lactamase Inhibitors Phase 3
30 Dihematoporphyrin Ether Phase 3
31 Hematoporphyrins Phase 3
32 Hematoporphyrin Derivative Phase 3
33 Ether Phase 3
34 Liver Extracts Phase 3
35 Antiemetics Phase 3
36 Cytochrome P-450 Enzyme Inhibitors Phase 3
37 Emetics Phase 3
38 Analgesics, Opioid Phase 3
39 Neurotransmitter Agents Phase 3
40 Dopamine Agents Phase 3
41 Central Nervous System Stimulants Phase 3
42 Dexmethylphenidate Hydrochloride Phase 3
43
Ethanol Approved Phase 2 64-17-5 702
44
Nedaplatin Approved, Investigational Phase 2 95734-82-0
45
Furosemide Approved, Vet_approved Phase 1, Phase 2 54-31-9 3440
46
Chlorpheniramine Approved Phase 1, Phase 2 132-22-9, 113-92-8 2725
47
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
48
Aminolevulinic acid Approved Phase 2 106-60-5 137
49
Phenylacetic acid Approved Phase 2 103-82-2 999
50
Sodium citrate Approved, Investigational Phase 2 68-04-2
51
Tamoxifen Approved Phase 2 10540-29-1 2733526
52
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
53
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
54
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
55
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
56
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
57
leucovorin Approved Phase 2 58-05-9 6006 143
58
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
59
Penicillamine Approved Phase 2 52-67-5 5852 4727
60
Copper Approved, Investigational Phase 2 7440-50-8 27099
61
Heparin Approved, Investigational Phase 2 9005-49-6 46507594 772
62
Tinzaparin Approved Phase 2 9041-08-1, 9005-49-6 25244225
63
Dalteparin Approved Phase 2 9005-49-6
64
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
65
Pregabalin Approved, Investigational Phase 2 148553-50-8 5486971
66
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
67
Donepezil Approved Phase 2 120014-06-4 3152
68
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
69
Fenofibrate Approved Phase 2 49562-28-9 3339
70
Masoprocol Approved, Investigational Phase 1, Phase 2 27686-84-6, 500-38-9 71398
71
Felbamate Approved Phase 1, Phase 2 25451-15-4 3331
72
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
73
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
74
Histamine Approved, Investigational Phase 2 51-45-6 774
75
Lapatinib Approved, Investigational Phase 1, Phase 2 231277-92-2, 388082-78-8 208908 9941095
76
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
77
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652